ArticleBMC health services research2020
Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.
Article in BMC health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Primary health care roles of community pharmacists in low- and middle-income countries: a mixed methods systematic review.BMC health services research · 2025Pooled it
- Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.PharmacoEconomics - open · 2026Article
- Cancer Medication Consumptions in Vietnam Between 2019 and 2023: An Analysis from the National Database.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Availability of essential medicines for non-communicable diseases: a scoping review of challenges and opportunities.BMJ global health · 2025Article
- A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.BMC public health · 2025Article
- Availability, price and affordability of anticancer medicines in Jiangsu Province, China: a cross-sectional survey study.Frontiers in public health · 2025Article
- Cancer Chemopreventive Effect of 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone on Diethylnitrosamine-Induced Early Stages of Hepatocarcinogenesis in Rats.Plants (Basel, Switzerland) · 2024Article
- Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China.BMC health services research · 2024Article
- Access to innovative anticancer medicines in China: a national survey on availability, price and affordability.BMJ open · 2024Observational
- Medicines policy, access and use in Mexico: a systematic literature review 2000-2022.Drugs in context · 2024Review
- Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand.International journal of health policy and management · 2024Article
- Access to advanced healthcare services and its associated factors among patients with cervical cancer in Addis Ababa, Ethiopia.Frontiers in oncology · 2024Article
- Cross-border utilization of cancer care by patients in the US and Mexico - a survey of Mexican oncologists.Globalization and health · 2023Article
- Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda.BMC health services research · 2023Article
- A comprehensive survey of cancer medicines prices, availability and affordability in Ghana.PloS one · 2023Article
- Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022.Cancer management and research · 2023Article
- Achieving health equity in cancer care in the Philippines.Ecancermedicalscience · 2023Article
- Access to anticancer medicines in public hospitals of Northwestern China.Frontiers in public health · 2023Article
- Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.Applied health economics and health policy · 2022Article
- Price, Availability and Affordability of Anti-Cancer Medicines in Addis Ababa, Ethiopia.Risk management and healthcare policy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMore alternatives have become available for the diagnosis and treatment of cancer in low- and middle-income countries. Because of increasing demands, governments are now facing a problem of limited affordability and availability of essential cancer medicines. Yet, precise information about the access to these medicines is limited, and the methodology is not very well developed. We assessed the availability and affordability of essential cancer medicines in Mexico, and compared their prices against those in other countries of the region.
methodsWe surveyed 21 public hospitals and 19 private pharmacies in 8 states of Mexico. Data were collected on the availability and prices of 49 essential cancer medicines. Prices were compared against those in Chile, Peru, Brazil, Colombia and PAHO's Strategic Fund.
resultsOf the various medicines, mean availability in public and private sector outlets was 61.2 and 67.5%, respectively. In the public sector, medicines covered by the public health insurance "People's Health Insurance" were more available. Only seven (public sector) and five (private sector) out of the 49 medicines were considered affordable. Public sector procurement prices were 41% lower than in other countries of the region.
conclusionsThe availability of essential cancer medicines, in the public and private sector, falls below World Health Organization's 80% target. The affordability remains suboptimal as well. A national health insurance scheme could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing policies are warranted to improve the affordability of cancer medicines in the private sector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.